Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009
Date:4/30/2009

age shares outstanding (000's) - basic 85,121 85,121 Weighted average shares outstanding (000's) - diluted 87,414 87,414 ----------------------------------- ------------------------------------- ----------------------------------- ------------------------------------- (in thousands of U.S.$, except Three months ended share and per share data) March 31, 2008 ------------------------------------------------------------------------- Reported Adjustment Adjusted REVENUE Royalty revenue $ 28,929 $ - $ 28,929 Product sales, net 47,727 - 47,727 License fees 53 (53) a - ----------------------------------- ------------------------------------- 76,709 (53) 76,656 ----------------------------------- ------------------------------------- EXPENSES License and royalty fees 4,371 - 4,371 Cost of products sold 25,849 - 25,849 Research and development 16,305 (1,566) b 14,739 Selling, general and administrative 27,843 (4,552) c 23,291 Depreciation and amortization 8,477 (7,585) d 892 In-process research and development 2,500 (2,500) e - ----------------------------------- ------------------------------------- 85,345 (16,203) 69,142 ----------------------------------- ------------------------------------- Operating income (loss) (8,636) 16,150 7,514 ----------------------------------- -----------------------
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21

Related biology technology :

1. Angiotech announces date of annual general meeting of shareholders
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call And Webcast
3. Angiotech Pharmaceuticals, Inc. announces License Agreement with Baxter International Inc.
4. Angiotech announces positive results from Bio-Seal(TM) clinical study
5. Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2008
6. Angiotech Pharmaceuticals, Inc. announces new Senior Secured Term Loan and Credit Facilities
7. Angiotech Pharmaceuticals announces time change of conference call and webcast
8. Angiotech announces termination of note purchase agreement with Ares Management and New Leaf Venture Partners
9. Angiotech Announces Webcast and Call-in Numbers for Annual and Special General Meeting of Shareholders
10. Angiotech Announces Extension of the Expiration Date of its Tender Offer for Senior Floating Rate Notes Due 2013 and 7.75% Senior Subordinated Notes Due 2014
11. Angiotech receives CE Mark approval of HemoStream(TM) Chronic Dialysis Catheter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... The Movement for Indefinite Life Extension ... extension technologies and awareness. The event is taking place ... March 21st 2015, in a live Google Hangout broadcast ... Founder of MILE, says, “Our lives are in our ... for Indefinite Life Extension is raising awareness about bio-sciences ...
(Date:2/26/2015)... IRVINE, Calif. , Feb. 26, 2015 /PRNewswire/ ... of age-defying aesthetic products for skin and hair ... Market Relations as agency of record for investor ... continues to improve our distribution, sales and diversification ... activities to current and prospective shareholders," stated Ali ...
(Date:2/26/2015)... BioEnterprise today announced that Northeast ... $2 billion in growth funding during the past 13 ... sources, state – including the Ohio Third Frontier - ... has been raised in the past five years. ... the BioEnterprise Midwest Healthcare Growth Capital  Report.   ...
(Date:2/26/2015)... (PRWEB) February 26, 2015 Already well ... gauging line by expanding its Length Gauge offerings with ... gauges. , Specifically, HEIDENHAIN’s pencil probe-style SPECTO ... force specification. Two new 1Vpp, 12mm stroke length ... force applications. One is a variant with a weak ...
Breaking Biology Technology:Indefinite Life Extension Activists Organize Online Demonstration 2Indefinite Life Extension Activists Organize Online Demonstration 3NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 2More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 3More Than $2 Billion Invested in Northeast Ohio Bioscience Start-Up Companies Since 2002 4Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2
...  Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced ... and Drug Administration,s (FDA) Oncologic Drugs Advisory Committee (ODAC) ... pixantrone for the treatment of relapsed or refractory aggressive ... more lines of prior therapy. ODAC is a panel ...
... in German . , Even the costliest ... carpet-weavers deliberately include tiny mistakes in their fine carpets, because ... as the nanotechnology industry would like to have them are ... team of physicists headed by Dr. Markus Lackinger from the ...
... Md. and CHERTSEY, England, Dec. 27, 2011  United ... its wholly-owned subsidiary, United Therapeutics Europe, Ltd., announced ... Francaise de Securite Sanitaire des Produits de Sante ... (treprostinil) for the treatment of pulmonary arterial hypertension ...
Cached Biology Technology:FDA's Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone New Drug Application on February 9, 2012 2FDA's Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone New Drug Application on February 9, 2012 3FDA's Oncologic Drugs Advisory Committee to Review Resubmitted Pixantrone New Drug Application on February 9, 2012 4The art of molecular carpet-weaving 2Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union 2Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union 3Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union 4Intravenous Remodulin Approved for the Treatment of Pulmonary Arterial Hypertension in Most of the European Union 5
(Date:2/18/2015)... SUNNYVALE, Calif. , Feb. 18, 2015  Cepheid (NASDAQ: ... be speaking at the following conferences, and invited investors to ... Conference, Boston, MA Tuesday, March 3, ... Institutional Investors Conference, Orlando, FL Wednesday, ... Accessing Live Webcasts To access the live webcasts for these ...
(Date:2/12/2015)... , Feb. 12, 2015   MedNet Solutions ... in clinical study management systems, has recently bolstered ... further distinguishing iMedNet as ... Organizations (CROs) and healthcare consultants.  Building on the ... customer referrals and numerous co-marketing opportunities), MedNet,s new ...
(Date:2/11/2015)... 11, 2015 According ... Control Market by Product (Cards and Readers, Biometrics, Controllers, ... Government, Industrial, Healthcare, Education) and By Geography - Global Forecast and ... the Access Control Market is expected to ... a CAGR of 10.6% between 2014 and ...
Breaking Biology News(10 mins):Cepheid to Webcast Upcoming Financial Presentations 2MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Access Control Market Worth $10.4 Billion by 2020 2Access Control Market Worth $10.4 Billion by 2020 3Access Control Market Worth $10.4 Billion by 2020 4
... the immune system and thwarting biological defenses. To ... the cancer,s chemical arsenal and boost a patient,s immune ... are rarely successful. Now, researchers have developed a ... both an immune-system booster and a chemical to counter ...
... Policy makers need to be cautious in setting new ... fuels as well as fuels from conventional crude oils ... in a paper published in the journal Environmental ... the first time confidential data from actual oil sands ...
... /PRNewswire-iReach/ -- Golden West Biologicals, Inc. is pleased to announce ... hosted by the American Association for Clinical Chemistry, at the ... 17 to 19. Golden West Biologicals (GWB) has ... products for the development of immunoassays since 1989.  This marks ...
Cached Biology News:Elegant delivery 2Elegant delivery 3Caution needed with new greenhouse gas emission standards 2
Alexa Fluor 647 anti-mouse Qa-2...
Formulation: Phosphate-buffered saline, pH 7.2, containing 0.09% sodium azide....
... normalization is essential for hunting and ... approaches, such as EST sequencing projects, ... TRIMMER-DIRECT kit is developed for normalization ... and intended for directional cloning. While ...
... The Luminex 100 Instrument System ... multi-analyte assays using Upstate's Beadlyte reagents. ... the Dell computer with software version ... Sheath Delivery System. Upstate offers $2000 ...
Biology Products: